Amphastar Pharmaceuticals, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; unaudited. Comparisons are with Q1 2023 unless otherwise stated. Amounts below are in U.S. dollars.
Business context
Amphastar develops, manufactures, markets and sells technically challenging generic and proprietary injectable, inhalation and intranasal medicines, as well as insulin active pharmaceutical ingredients (API). Its reportable segments are finished pharmaceutical products and API. In Q1 2024, the company began assuming BAQSIMI distribution from Lilly in the United States and certain European countries; distribution in remaining territories is expected to transfer country by country during 2024.
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Total net revenue | $171.8 million | $140.0 million | +22.7% |
| Gross profit | $90.1 million | $73.8 million | +22.0% |
| Gross margin | 52.4% | 52.7% | Down 0.3 percentage points |
| Operating income | $48.0 million | $33.4 million | +43.6% |
| Net income | $43.2 million | $26.0 million | +65.9% |
| Diluted earnings per share | $0.81 | $0.50 | +62.0% |
| Cash provided by operations | $55.3 million | $40.4 million | +$14.9 million |
Product revenue was $157.6 million, up 12.6%; other revenue was $14.2 million, primarily BAQSIMI sales by Lilly recorded net under the transition services arrangement. Finished pharmaceutical products revenue, including BAQSIMI revenue, was $170.1 million; API revenue was $1.7 million, down 58%. API generated a gross loss of $6.0 million, compared with a $2.3 million loss a year earlier.
Revenue growth reflected BAQSIMI, higher glucagon, epinephrine and phytonadione sales, and Primatene MIST growth. Enoxaparin, naloxone, lidocaine and API sales declined. The 2024 effective tax rate was 8.6%, versus 20.1%, primarily due to the timing of discrete tax items. Non-operating results included a $5.9 million net gain in other income, primarily related to foreign-currency fluctuations and interest-rate-swap mark-to-market changes; interest expense rose to $8.6 million from $0.4 million, reflecting acquisition financing and convertible notes.
Liquidity, cash flow and debt
- Cash and cash equivalents were $201.1 million at March 31, 2024, versus $144.3 million at year-end; short-term investments were $88.4 million and long-term investments $15.2 million. Working capital was $299.9 million, up from $264.2 million.
- Operating cash flow was $55.3 million. Investing activities provided $15.2 million, mainly reflecting net investment maturities; capital expenditures were $8.8 million. Financing activities used $13.6 million, primarily for equity-plan share settlements and related withholding taxes.
- Total debt was $607.8 million, including $345.0 million of 2.0% convertible notes due 2029 and a $250.0 million term loan due 2028. The company also had $4.1 million outstanding under a new ICBC facility. Management reported compliance with all debt covenants.
- Management believes cash reserves, operating cash flows and borrowing availability will fund operations for at least 12 months from the filing date. It expects facility expansion and development needs to raise cash requirements; planned manufacturing-facility expansion is expected to be funded primarily from operating cash flow.
Material changes and management commentary
- BAQSIMI contributed $13.8 million of product revenue after Amphastar assumed distribution in certain territories, plus $14.2 million of other revenue for sales Lilly continued to make on Amphastar’s behalf. Lilly-reported worldwide BAQSIMI sales were $24.6 million. The net-versus-gross reporting transition affects reported revenue and cost comparability.
- Gross margin edged down despite higher gross profit. Management cited increased BAQSIMI-related depreciation and amortization, labor and component costs, and inventory and purchase-commitment adjustments. Inventory-related charges were $5.7 million, versus $1.9 million in Q1 2023.
- Management expects increased costs for labor and certain APIs and components, but believes these may be offset by higher-margin products, including BAQSIMI, glucagon, vasopressin, ganirelix and regadenoson, and anticipated 2024 launches. No numerical revenue or earnings guidance is provided in the filing text.
- R&D expense fell 14% to $17.0 million, mainly due to lower clinical-trial and materials spending after 2023 pipeline ramp-up. Management expects annual R&D expense to rise as insulin and inhalation candidate trials progress.
- API sales are expected to remain below historical levels while MannKind qualifies Amphastar’s upgraded recombinant human insulin. The company plans to relaunch medroxyprogesterone in the second half of 2024 after qualifying its ANP subsidiary to manufacture the API.
- Backlog was approximately $6.8 million, primarily due to competitor shortages and supplier constraints; management cautions that backlog has not historically been a reliable indicator of overall revenue or performance.
Risks, contingencies and unusual items
- Supply-chain exposure includes materials available from single or limited sources and foreign suppliers. Competitor supply shortages have supported demand for some products, but reversals in supply conditions can affect sales; management expects fluctuation in epinephrine and other products and competitive volatility in naloxone and enoxaparin.
- An FDA pre-approval and cGMP inspection of the Rancho Cucamonga facility in February–March 2024 resulted in several Form 483 observations. The company responded and believes no significant further action will be necessary; the filing does not establish the final regulatory outcome.
- The company cites inflation, rising interest rates, geopolitical conflicts, healthcare pricing and reimbursement changes, regulatory approval and compliance, product competition, and manufacturing or supplier interruptions as risks. It reports no material change to previously disclosed risk factors.
- Amphastar is subject to ordinary-course claims and litigation. Management does not expect their ultimate resolution to materially adversely affect financial position, results or cash flows, while noting outcomes are unpredictable. Purchase commitments for equipment and raw materials totaled approximately $68.5 million.
- Customer concentration is significant: McKesson, Cencora and Cardinal together represented 61% of Q1 revenue; Lilly represented 8%. The four major customers collectively accounted for substantial receivables and revenue.
Most important facts for investors to verify
- How BAQSIMI territory transfers, direct distribution, and the shift from net to product-revenue reporting affect comparable sales, margins and cash collection.
- Whether gross-margin pressure, including the $5.7 million inventory and purchase-commitment charge, persists and whether higher-margin products offset input and labor costs.
- Progress and timing of MannKind’s qualification of upgraded insulin, the planned medroxyprogesterone relaunch, pipeline trials, regulatory reviews and anticipated product launches.
- Whether working-capital growth, including receivables and inventory, converts to cash, and whether liquidity remains adequate alongside debt service, capital spending and acquisition-related obligations.
- The outcome of the FDA Form 483 observations, exposure to concentrated distributors and limited-source suppliers, and the effect of changing competitor supply conditions on product demand.